

Pneumatic tube system transport does not alter platelet function in optical and whole blood aggregometry, prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen in patients on anti-platelet drug therapy

Dietmar Enko^{1,2}, Harald Mangge², Andreas Münch³, Tobias Niedrist², Elisabeth Mahla^{3,4}, Helfried Metzler³, Florian Prüller^{*2,4}

¹Institute of Clinical Chemistry and Laboratory Medicine, General Hospital Steyr, Steyr, Austria

²Clinical Institute of Medical and Laboratory Diagnostics, Medical University Graz, Graz, Austria

³Department of Anesthesiology and Intensive Care Medicine, Medical University Graz, Graz, Austria

⁴Research Unit "Perioperative Platelet Function", Medical University of Graz, Graz, Austria

*Corresponding author: florian.prueller@medunigraz.at

Abstract

Introduction: The aim of this study was to assess pneumatic tube system (PTS) alteration on platelet function by the light transmission aggregometry (LTA) and whole blood aggregometry (WBA) method, and on the results of platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen.

Materials and methods: Venous blood was collected into six 4.5 mL VACUETTE® 9NC coagulation sodium citrate 3.8% tubes (Greiner Bio-One International GmbH, Kremsmünster, Austria) from 49 intensive care unit (ICU) patients on dual anti-platelet therapy and immediately hand carried to the central laboratory. Blood samples were divided into 2 Groups: Group 1 samples (N = 49) underwent PTS (4 m/s) transport from the central laboratory to the distant laboratory and back to the central laboratory, whereas Group 2 samples (N = 49) were excluded from PTS forces. In both groups, LTA and WBA stimulated with collagen, adenosine-5'-diphosphate (ADP), arachidonic acid (AA) and thrombin-receptor-activated-peptide 6 (TRAP-6) as well as platelet count, PT, APTT, and fibrinogen were performed.

Results: No statistically significant differences were observed between blood samples with (Group 1) and without (Group 2) PTS transport (P values from 0.064 – 0.968). The AA-induced LTA (bias: 68.57%) exceeded the bias acceptance limit of $\leq 25\%$.

Conclusions: Blood sample transportation with computer controlled PTS in our hospital had no statistically significant effects on platelet aggregation determined in patients with anti-platelet therapy. Although AA induced LTA showed a significant bias, the diagnostic accuracy was not influenced.

Key words: platelets; platelet aggregation; platelet function tests; clinical laboratory services; preanalytical phase

Received: July 13, 2016

Accepted: January 14, 2017

Introduction

Platelets play a key role in primary hemostasis. The principal function is stopping hemorrhage and preventing blood loss, when vessel walls are injured (1). Platelets interacting with the exposed matrix adhere, become activated, and as a consequence bind further platelets to form a thrombus limited in size. Specific platelet receptors are involved in each of these phases (2).

Platelet function testing has become essential for identifying patients with platelet dysfunction and for monitoring modern anti-platelet therapy. In hemostasis laboratories, platelet aggregometry has been established one of the most widely used platelet function testing procedures (3). Light transmission aggregometry (LTA), which was developed in 1962 by Born and O'Brien, and imped-

ance whole blood aggregometry (WBA) are the two main types of methodologies available (3-6).

Since platelets are sensitive to artificial manipulation, preanalytical variables may influence hemostasis testing in laboratories. The tourniquet application time is reported biasing platelet function testing by multiple electrode aggregometry (MEA) (Multiplate®) (7). Moreover, in clinical routine laboratories different vacuum tubes may represent a relevant source of variability on the determination of the mean platelet volume and platelet distribution width (8). Recently, one study concluded that physical exercise in cold water also represents a stress factor, which may cause increased platelet counts (9). Preanalytical variables are often outside the control of hemostasis laboratories and the leading causes of diagnostic error (10). Several crucial steps in the preanalytical phase, such as correct blood collection, blood sample handling, transport and storage of specimens are essential parts to get valid and timely laboratory test results (11).

Over the last years, in many hospitals pneumatic tube systems (PTS) have been established for blood sample transport between departments and outpatient clinics. PTS is considered an efficient and cost effective transport solution specially designed to handle automated blood specimen transport in routine and emergency settings. Nev-

ertheless, blood samples transported by PTS are often subjected to high speed (up to 7.6 m/s) accompanied by rapid acceleration and deceleration causing shear stress (12). Changes in air pressure, vibrations and shaking of blood samples are considered to affect various laboratory parameters including coagulation assays (13).

In the literature, various studies have been performed on the effects of PTS on popular point-of-care thromboelastometry (ROTEM®) analysis. A study by Amann *et al.* including 20 healthy volunteers reported statistically significant changes (P values < 0.001) in multiple ROTEM® parameters transported by PTS (14). In contrast, Colucci *et al.* observed no statistically significant differences (P values from 0.381 – 0.978) between pneumatic delivery and hand carried transport in 30 whole blood samples of healthy volunteers (15). While study results of PTS effects on ROTEM® analyses are discordant, only few data are available about platelet alteration after blood sample transportation with PTS on LTA and WBA, respectively. An overview on previously published original research articles investigating PTS effects on platelet function testing is given in Table 1.

The aim of the present study was to investigate the effect of PTS on the results of LTA, WBA, platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen.

TABLE 1. Previously published original research articles investigating pneumatic tube system effects on platelet function testing

Year	Author	Journal	Subjects, N	Methods	PTS effect	Reference
2004	Dyszkiewicz-Korpanty <i>et al.</i>	JTH	27	PFA-100™ Impedance WBA	CADP ↑ Ω ↓	18
2005	Walin <i>et al.</i>	CCLM	28	PFA-100™	No effect	19
2009	Bollinger <i>et al.</i>	Platelets	50	Multiplate®	Aggregation ↓	20
2010	Hübner <i>et al.</i>	Clin Lab	15	PFA-100™ Optical LTA	CADP ↑ Aggregation ↓	21
2013	Glas <i>et al.</i>	Platelets	12	Multiplate® ROTEM	Aggregation ↓ EXTEM CT ↑	22
2013	Thalén <i>et al.</i>	Thromb Res	58	Multiplate®	Aggregation ↓	23

JTH – Journal of Thrombosis and Haemostasis. CCLM – Clinical Chemistry and Laboratory Medicine. Clin Lab – Clinical Laboratory. Thromb Res – Thrombosis Research. PFA – platelet function analyzer. CADP – collagen membrane coated with ADP. WBA – whole blood aggregometry. Ω – impedance. LTA – light transmission aggregometry. ROTEM – rotational thrombelastometry. EXTEM – extrinsic rotational thrombelastometry. CT – clotting time. ↑ – increased. ↓ – decreased.

Materials and methods

Subjects

This experimental study was conducted at the Medical University of Graz (Graz, Austria). The study period was from 01th January to 31th December 2008. A total of 49 patients from the Intensive Care Unit (ICU) of the Department of Anesthesiology and Intensive Care Medicine, who were on full dual anti-platelet drug therapy with 100 mg acetyl-salicylate acid and 75 mg clopidogrel daily, were included. Thirty-six (0.74) patients were male and 13 (0.26) were female. The median age was 65 (range: 47 – 89) years. This study was carried out in accordance with the latest version of the Declaration of Helsinki given by the World Medical Association. The ethical approval was provided by the Ethical Committee of the Medical University of Graz (Graz, Austria). All study subjects gave written informed consent for participation in the study.

Blood sampling

Blood sampling was done in the morning without obligatory fasting state. From all 49 study participants venous blood was collected into six 4.5 mL VACUETTE® 9NC coagulation sodium citrate 3.8% tubes (Greiner Bio-One International GmbH, Kremsmünster, Austria). Immediately after the venipuncture, all vacuum tubes (6 x 49) were gently inverted five times and hand carried by our laboratory personal to the core laboratory of our hospital. In the central laboratory blood samples were divided in Group 1 (3 x 49 tubes) and Group 2 (3 x 49 tubes) without delay. Group 1 blood samples were transported with the PTS from the central laboratory to the distant laboratory and returned again with the PTS from the distant laboratory to the central laboratory. Group 2 blood samples were excluded from PTS transport.

After transport all collected blood samples stored 30 minutes at room temperature. The original vacuum tubes 1 (Group 1 and Group 2) were gently inverted 5 times and 8 x 450 µL were pipetted in duplicates in each channel of a 4 channel Chronolog 700 Aggregometer (Chronolog Corporation, Havertown, Pennsylvania, USA) to perform

impedance WBA. The original vacuum tubes 2 and 3 (Group 1 and Group 2) were centrifuged at 110 x g for 15 minutes at room temperature to obtain platelet rich plasma (PRP), using a GS-15 centrifuge (Beckman Coulter GmbH, Vienna, Austria). The PRP was removed from tubes 2 and 3 and mixed in 15 mL Eppendorf Conical Tubes® (Eppendorf Austria GmbH, Vienna, Austria) for further analysis. From the Eppendorf Conical Tubes®, 8 x 450 µL were pipetted in duplicates in each channel of a 4 channel Chronolog 700 Aggregometer (Chronolog Corporation, Havertown, Pennsylvania, USA) to perform LTA. Platelet count was performed from PRP on the Sysmex XE-2100™ Automated Hematology System (Sysmex Austria GmbH, Vienna, Austria). Approximately 2.7 mL blood was left in each of the original vacuum tubes 2 and 3 (Group 1 and Group 2), which were centrifuged once more at 2800 x g for 15 minutes at room temperature to obtain platelet poor plasma (PPP). PPP was used for PT, APTT and fibrinogen measurements and for blank value determinations of the aggregometer.

Methods

Pneumatic tube system (PTS)

Blood samples of Group 1 (3 x 49 tubes) were transported by a computer controlled PTS (Swisslog Rohrpostsysteme GmbH, Westerstede, Germany) using standard pneumatic tube carriers. One distance was about 500 m with a mean transit time of 2 min. As a result Group 1 samples (3 x 49 tubes) were subjected a twice done acceleration and deceleration during transportation process with PTS, whereas Group 2 samples (3 x 49 tubes) were excluded from PTS transport.

After computer controlled acceleration an average velocity of 4m/s was used. Special receiving stations with controlled deceleration delivered softly the pneumatic tube carrier on special exit conveyor belts.

Light transmission aggregometry (LTA)

LTA was performed in duplicates using a 4 channel Chronolog 700 Aggregometer (Chronolog Corporation, Havertown, Pennsylvania, USA). After pipetting 450 µL PRP in each channel, aggregation was induced using final concentrations of 2 µg/mL col-

lagen (Chronolog Corporation, Havertown, Pennsylvania, USA), 10 $\mu\text{mol/L}$ adenosine 5'-diphosphate (ADP) (Sigma-Aldrich Handels GmbH, Vienna, Austria), 0.5 mmol/L arachidonic acid (AA) (Chronolog Corporation, Havertown, Pennsylvania, USA), and 40 $\mu\text{mol/L}$ thrombin receptor-activated peptide 6 (TRAP-6) (Bachem Distribution Services GmbH, Weil/Rhein, Germany). Light transmission (% aggregation and area under the curve (AUC)) was measured in Group 1 and 2 and compared statistically. A maximal amplitude of < 5% and an AUC of < 75 were interpreted as total inhibition of platelet function depending on the above mentioned platelet aggregation inducing reagents. Daily quality control (QC) measurements were performed with normal plasma of healthy volunteers. Coefficients of variation (CV) for light transmission % and AUC were as follows: collagen - 4.01 and 3.18%, respectively; ADP - 3.38 and 6.53%, respectively; AA - 2.19 and 4.94%, respectively; TRAP - 4.14 and 2.5%, respectively.

Impedance whole blood aggregometry (WBA)

Impedance WBA was performed in duplicates using a 4 channel Chronolog 700 Aggregometer (Chronolog Corporation, Havertown, Pennsylvania, USA). After pipetting 450 μL whole blood in each channel, aggregation was induced with the same agents and final concentrations as described above. The impedance (Ω and AUC) was measured in Group 1 and 2 samples and compared statistically. A maximal impedance of < 0.5 Ω and an AUC of < 5 and were interpreted as total inhibition of platelet function depending on the above mentioned platelet aggregation inducing reagents. Daily QC measurements were performed with normal plasma of healthy volunteers. Coefficients of variation for impedance Ω and AUC were as follows: collagen - 4.06 and 10.9%, respectively; ADP - 13.47 and 12.38%, respectively; AA - 13.72 and 8.72%, respectively; TRAP - 12.06 and 10.52%, respectively.

Coagulation parameters

The number of platelets was determined on the Sysmex XE-2100TM Automated Hematology System (Sysmex Austria GmbH, Vienna, Austria). The PT (Thromborel[®] S reagent, Siemens Healthcare Diagnostics GmbH, Vienna, Austria), APTT (Pathrom-

tin[®] SL reagent, Siemens Healthcare Diagnostics GmbH, Vienna, Austria), and fibrinogen (Multifibren[®] U reagent, Siemens Healthcare Diagnostics GmbH, Vienna, Austria) were measured on the Siemens/Dade Behring BCS XP Analyzer Automated Coagulation System (Siemens Healthcare Diagnostics GmbH, Vienna, Austria). Daily QC measurements were performed with commercially available control material within the normal and pathological ranges (Control Plasma N and P (Siemens Healthcare Diagnostics GmbH, Vienna, Austria): PT 73.0 - 109.0 % and 32 - 48 %; APTT 28.0 - 38.0 s and 70 - 105 s; fibrinogen 2.2 - 3.2 g/L and 0.6 - 1.4 g/L, respectively; e-CHECK[®](XE) (Sysmex Austria GmbH): platelet counts 195 - 240 G/L, 30 - 75 G/L and 480 - 580 G/L). Inter-assay precision was calculated with results of minimum 20 consecutive days. One ten-fold measurement was performed at one day to determine the intra-assay precision. The intra- and inter-assay CV were as follows: for PT 1.71 and 3.26%, respectively; for PT-INR 2.43 and 3.24%, respectively; for APTT 2.31 and 2.83%, respectively; for fibrinogen 1.23 and 2.87%, respectively; and for platelet count 1.23 and 3.4%, respectively.

Statistical analysis

The distribution of data was calculated with the Kolmogorov-Smirnov test. The non-parametric Wilcoxon test was used for comparisons of parameters between Group 1 and Group 2. Not normally distributed data were described in medians (Q1 - Q3). A P-value < 0.05 was considered statistically significant. Bias calculation was performed and compared with available acceptance criteria in accordance with the Milano hierarchy (16). The calculated biases were compared to the acceptance limits based on the Clinical Laboratory Improvement Amendments (CLIA) for analytical quality (17). SPSS Statistics for Windows version 22.0 (IBM SPSS Inc., Chicago, Illinois, USA) was used for statistical analysis.

Results

The results of platelet function testing with LTA and WBA, and the coagulation parameters (i.e., platelet count, PT, APTT, and fibrinogen) between blood samples of Group 1 (N = 49) and Group 2 (N

= 49) and the mean bias are shown in Table 2. All parameters investigated in the present study were not normally distributed and are presented in medians (Q1 – Q3). No statistically significant differences were observed between blood samples transported with (Group 1) and without PTS (Group 2) (P values from 0.064 – 0.968).

Discussion

To the best of our knowledge, this is the first study reporting data about PTS effects on both, optical aggregometry as well as impedance aggregometry measurements in patients on anti-platelet drug therapy. The results referred only to patients on dual acetyl-salicylate acid and clopidogrel therapy

TABLE 2. Light transmission, impedance and coagulation parameters

LTA		Group 1 (N = 49)	Group 2 (N = 49)	P value	Bias (%)	Bias criteria (%)
Collagen-induced	%	28.0 (16.8 – 47.0)	28.5 (14.0 – 50.0)	0.592	1.75	≤ 25
	AUC	222.2 (112.1 – 337.1)	227.7 (99.3 – 376.4)	0.682	2.42	≤ 25
ADP-induced	%	33.0 (24.0 – 40.8)	35.5 (21.0 – 43.0)	0.406	7.04	≤ 25
	AUC	280.8 (138.6 – 338.6)	279.9 (127.2 – 362.4)	0.568	0.32	≤ 25
AA-induced	%	2.0 (1.0 – 11.0)	2.0 (1.0 – 16.3)	0.741	0.0	≤ 25
	AUC	23.6 (0.25 – 51.35)	14.0 (0.0 – 52.5)	0.064	68.57	≤ 25
TRAP-6-induced	%	51.0 (35.0 – 59.0)	52.0 (43.5 – 62.0)	0.141	1.92	≤ 25
	AUC	441.6 (290.6 – 512.8)	438.6 (348.3 – 521.4)	0.915	0.68	≤ 25
WBA						
Collagen-induced	Ω	8.0 (5.0 – 11.0)	8.0 (4.0 – 12.0)	0.444	0.0	≤ 25
	AUC	44.8 (18.8 – 66.1)	40.1 (18.6 – 74.9)	0.165	11.72	≤ 25
ADP-induced	Ω	2.0 (0.0 – 5.3)	2.5 (1.0 – 7.0)	0.180	20.0	≤ 25
	AUC	8.55 (0.0 – 31.6)	11.0 (0.0 – 42.5)	0.361	22.27	≤ 25
AA-induced	Ω	0.0 (0.0 – 0.0)	0.0 (0.0 – 0.0)	0.549	0.0	≤ 25
	AUC	0.0 (0.0 – 0.0)	0.0 (0.0 – 0.0)	0.286	0.0	≤ 25
TRAP-6-induced	Ω	3.0 (1.0 – 9.0)	3.0 (1.0 – 9.0)	0.733	0.0	≤ 25
	AUC	22.9 (5.6 – 70.7)	25.2 (2.1 – 65.4)	0.266	9.13	≤ 25
Coagulation parameters						
Platelets (WB)	x 10 ⁹ /L	94.0 (66.0 – 142.0)	94.0 (66.0 – 139.0)	0.418	0.0	≤ 25
Platelets (PRP)	x 10 ⁹ /L	175.0 (114.0 – 267.0)	170.0 (123.0 – 267.0)	0.176	2.94	≤ 25
PT	INR	1.1 (1.0 – 1.3)	1.1 (1.0 – 1.3)	0.968	0.0	≤ 15
	%	91.0 (72.0 – 107.0)	92.0 (75.0 – 107.0)	0.909	1.09	≤ 15
APTT	s	42.4 (38.3 – 49.8)	43.5 (38.3 – 49.7)	0.426	2.53	≤ 15
Fibrinogen	g/L	6.3 (3.6 – 7.9)	6.1 (3.6 – 8.0)	0.726	3.30	≤ 20

LTA - light transmission aggregometry. WBA - whole blood aggregometry. Ω - impedance. Group 1 - blood samples transported with pneumatic tube system (PTS). Group 2 - blood samples transported without PTS. ADP - adenosine diphosphate. AA - arachidonic acid. TRAP-6 - thrombin receptor-activated peptide 6. AUC - area under the curve. WB - whole blood. PRP - platelet rich plasma. PT - prothrombin time. INR - international normalized ratio. APTT - activated partial thromboplastin time. Differences between Group 1 and Group 2 were evaluated using the Wilcoxon test. Data are presented as medians (Q1 – Q3). P < 0.05 was considered statistically significant. Bias criteria according to reference 17.

and not on healthy individuals. Overall 49 study participants were included in this experimental study.

In comparison, previously published studies on the subject of PTS effects on platelet aggregation tests were designed with 12 to 58 subjects (18 - 23) (Table 1). Two studies, comprising 58 and 50 individuals, observed significant influence on impedance WBA with a Multiplate® analyzer (20,23). In both studies, detailed information about speed of sample transport and other characteristics of the PTS, that may strongly affect pre-analytical quality are lacking. Reducing speed is considered to avoid pre-analytical alteration of blood samples (24). However, different PTS configurations could be a potential reason for various results and observations of published data.

In the present study both methodologies, namely LTA as well as WBA were performed to study PTS effects on platelet function. These methods are usually performed in specialized clinical hemostasis laboratories. Beside these traditional tests, previously published studies about PTS effects on platelet function used especially modern commercially available point-of-care testing methods, such as the multichannel WBA with Multiplate® system or the relatively simple PFA-100™ technology, measuring platelet aggregation as a function of the time it takes to occlude the aperture (25).

Poor correlation among different platelet function testing modalities may be one limitation in comparison and clinical interpretation of different study results. Moreover, different agonists are used to induce platelet aggregation. Herein we used the aggregation agonists collagen (2 µg/mL), ADP (10 µmol/L), AA (0.5 mmol/L), and TRAP-6 (40 µmol/L) with final concentrations as recommended by the manufacturer. In comparison Dyszkiewicz-Korpanty *et al.* recruited 27 healthy volunteers and used collagen (2 µg/mL), ADP (10 µmol/L) and AA (0.5 mmol/L) to perform impedance WBA (18), whereas Hübner *et al.* recruited 15 healthy subjects and used collagen (2 µg/mL and 5 µg/mL), ADP (10 µmol/L) and ristocetin (1.25 g/L) to perform optical LTA (20). One previously published study about PTS effects on the Multiplate® system

was performed with 58 individuals (32 healthy individuals, 14 patients with cardiovascular disease treated with aspirin and/or clopidogrel, 8 patients from an ICU, and 4 patients from a coagulation clinic) using final concentrations of 0.0032 µg collagen, 0.0065 µmol ADP, 0.4839 µmol AA, 0.3076 µg ristocetin and 0.0322 µmol TRAP in each corresponding well (23). Another study on the Multiplate® system evaluated 50 patients with acetylsalicylate acid therapy using AA (0.5 mmol/L) and TRAP (32 µmol/L) only (20).

Considering these various study designs performed with different agonists and concentrations, the major limitation of data comparison is the lack of standardization in platelet function testing. Widespread accepted uniform guidelines on how laboratories should perform clinical testing for disorders of platelet function are still not available (26,27). Results of two surveys of the North American Specialized Coagulation Laboratory Association (NASCOLA) demonstrated that agonist concentrations varied widely and that various methods were used to obtain reference intervals for platelet aggregation testing (26). Although LTA is considered to be the "gold standard" for *in vitro* platelet function testing in both clinical and research laboratories, no evidence-based guidelines for the performance and interpretation of studies with this technique are established yet (28,29). Moreover no proper commercial controls are available for the different platelet function assays to examine the validity of the test results.

In the present study the mean bias of the investigated parameters between blood samples transported with (Group 1) and without PTS (Group 2) ranged from 0.0 to 68.57%. Compared to the available acceptance criteria in accordance with the Milano hierarchy (16,17), analytical performance evaluation studies may be influenced by the measurement quality, the actual test method used, and the investigated study population. Therefore standardized platelet function testing procedures with commercially available QC material for LTA and WBA is required in order to improve analytical quality and reproducibility.

The major limitation of this study is that healthy subjects, who were not on anti-platelet therapy, were not included. We cannot omit a protective effect on acetyl-salicylate acid and clopidogrel during transportation. Nevertheless, the added value of this study is that potential PTS effects were investigated on platelet function testing with the LTA as well as the WBA method.

In conclusion, blood sample transportation with soft motion computer controlled PTS, as installed in our hospital, had no statistically significant effects on platelet aggregation measured with optical and impedance aggregometry in patients with

dual anti-platelet therapy. Although AA induced LTA showed a significant bias, the diagnostic accuracy was not influenced at all. Further investigation on healthy subjects without anti-platelet therapy should be performed.

Acknowledgements

We are grateful to the medical laboratory technicians of the coagulation and the platelet function laboratory, who performed the experimental work.

Potential conflict of interest

None declared.

References

1. Broos K, De Meyer SF, Feys HB, Vanhoorelbeke K, Deckmyn H. Blood platelet biochemistry. *Thromb Res* 2012;129:245-9. <https://doi.org/10.1016/j.thromres.2011.11.002>.
2. Clemetson KJ. Platelets and primary haemostasis. *Thromb Res* 2012;129:220-4. <https://doi.org/10.1016/j.thromres.2011.11.036>.
3. Favaloro EJ, Lippi G, Franchini M. Contemporary platelet function testing. *Clin Chem Lab Med* 2010;48:579-98. <https://doi.org/10.1515/CCLM.2010.121>.
4. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. *Nature* 1962;194:927-9. <https://doi.org/10.1038/194927b0>.
5. O'Brien JR. The adhesiveness of native platelets and its prevention. *J Clin Pathol* 1961;14:140-9. <https://doi.org/10.1136/jcp.14.2.140>.
6. Cardinal DC, Flower RJ. The study of platelet aggregation in whole blood [proceedings]. *Br J Pharmacol* 1979;66:94P-95P.
7. Lima-Oliveira G, Lippi G, Salvagno GL, Gaino S, Poli G, Gelati M, et al. Venous stasis and whole blood platelet aggregometry: a question of data reliability and patient safety. *Blood Coagul Fibrinolysis* 2015;26:665-8. <https://doi.org/10.1097/MBC.0000000000000342>.
8. Lima-Oliveira G, Lippi G, Salvagno GL, Montagnana M, Poli G, Solero GP, et al. K(3)EDTA vacuum tubes validation for routine hematological testing. *ISRN Hematol* 2012;2012:875357. <https://doi.org/10.5402/2012/875357>.
9. Lombardi G, Ricci C, Banfi G. Effect of winter swimming on haematological parameters. *Biochem Med (Zagreb)* 2011;21:71-8. <https://doi.org/10.11613/BM.2011.014>.
10. Favaloro EJ, Lippi G, Adcock DM. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis? *Semin Thromb Hemost* 2008;34:612-34. <https://doi.org/10.1055/s-0028-1104540>.
11. Lima-Oliveira G, Lippi G, Salvagno GL, Dima F, Brocco G, Picheth G, et al. Management of preanalytical phase for routine hematological testing: is the pneumatic tube system a source of laboratory variability or an important facility tool? *Int J Lab Hematol* 2014;36:e37-40. <https://doi.org/10.1111/ijlh.12143>.
12. Kratz A, Salem RO, Van Cott EM. Effects of a pneumatic tube system on routine and novel hematology and coagulation parameters in healthy volunteers. *Arch Pathol Lab Med* 2007;131:293-6.
13. Kocak FE, Yöntem M, Yücel O, Cilo M, Genc O, Meral A. The effects of transport by pneumatic tube system on blood cell count, erythrocyte sedimentation and coagulation tests. *Biochem Med (Zagreb)* 2013;23:206-10. <https://doi.org/10.11613/BM.2013.024>.
14. Amann G, Zehntner C, Marti F, Colucci G. Effect of acceleration forces during transport through a pneumatic tube system on ROTEM® analysis. *Clin Chem Lab Med* 2012;50:1335-42. <https://doi.org/10.1515/cclm-2011-0800>.
15. Colucci G, Giabbani E, Barizzi G, Urwyler N, Alberio L. Laboratory-based ROTEM(®) analysis: implementing pneumatic tube transport and real-time graphic transmission. *Int J Lab Hematol* 2011;33:441-6. <https://doi.org/10.1111/j.1751-553X.2011.01303.x>.
16. Sandberg S, Fraser CG, Horvath AR, Jansen R, Jones G, Oosterhuis W, et al. Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. *Clin Chem Lab Med* 2015;53:833-5. <https://doi.org/10.1515/cclm-2015-0067>.
17. Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)-HCFA. Final rule with comment period. *Fed Regist* 1992;57:7002-186.

18. Dyszkiewicz-Korpanty A, Quinton R, Yassine J, Sarode R. The effect of a pneumatic tube transport system on PFA-100 trade mark closure time and whole blood platelet aggregation. *J Thromb Haemost* 2004;2:354-6. <https://doi.org/10.1111/j.1538-7836.2004.0584e.x>.
19. Wallin O, Söderberg J, Grankvist K, Jonsson PA, Hultdin J. Preanalytical effects of pneumatic tube transport on routine haematology, coagulation parameters, platelet function and global coagulation. *Clin Chem Lab Med* 2008;46:1443-9. <https://doi.org/10.1515/CCLM.2008.288>.
20. Bollinger D, Seeberger MD, Tanaka KA, Dell-Kuster S, Gregor M, Zenklusen U, et al. Pre-analytical effects of pneumatic tube transport on impedance platelet aggregometry. *Platelets* 2009;20:458-65. <https://doi.org/10.3109/09537100903236462>.
21. Hübner U, Böckel-Frohnhofer N, Hummel B, Geisel J. The effect of a pneumatic tube transport system on platelet aggregation using optical aggregometry and the PFA-100. *Clin Lab* 2010;56:59-64.
22. Glas M, Mauer D, Kassas H, Volk T, Kreuer S. Sample transport by pneumatic tube system alters results of multiple electrode aggregometry but not rotational thrombelastometry. *Platelets* 2013;24:454-61. <https://doi.org/10.3109/09537104.2012.718383>.
23. Thalén S, Forsling I, Eintrei J, Söderblom L, Antovic JP. Pneumatic tube transport affects platelet function measured by multiplate electrode aggregometry. *Thromb Res* 2013;132:77-80. <https://doi.org/10.1016/j.thromres.2013.04.020>.
24. Tiwari AK, Pandey P, Dixit S, Raina V. Speed of sample transportation by a pneumatic tube system can influence the degree of hemolysis. *Clin Chem Lab Med* 2011;50:471-4.
25. Harrison P. Assessment of platelet function in the laboratory. *Hämostaseologie* 2009;29:25-31.
26. Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CP; North American Specialized Coagulation Laboratory Association. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. *Thromb Haemost* 2005; 93:549-53. <https://doi.org/10.1160/th04-10-0670>.
27. Linnemann B, Schwonberg J, Mani H, Prochnow S, Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. *J Thromb Haemost* 2008;6:677-83. <https://doi.org/10.1111/j.1538-7836.2008.02891.x>.
28. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. *J Thromb Haemost* 2009;7:1029. <https://doi.org/10.1111/j.1538-7836.2009.03458.x>.
29. Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. *J Thromb Haemost* 2013;11:1183-89. <https://doi.org/10.1111/jth.12231>.